Nuveen’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Nuveen’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-400	Closed	-$64K	–	3578
2022 Q1	$64K	Hold	400	–	–	﹤0.01%	3269
2021 Q4	$111K	Hold	400	–	–	﹤0.01%	3278
2021 Q3	$176K	Hold	400	–	–	﹤0.01%	3288
2021 Q2	$169K	Buy	+400	New	+$173K	﹤0.01%	3259

Other funds holding FNCH

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Nuveen's FNCH Position: Q2 2022 in Review

Nuveen sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2022, closing a stake of 400 shares — an estimated $64K sold.

Nuveen first reported a position in FNCH in Q2 2021 and held it in 4 quarters. The position peaked at $176K in Q3 2021. 46 funds tracked by Wall St. Rank hold FNCH as of Q2 2022.

Nuveen reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Nuveen sold 400 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2022, an estimated $64K.
Nuveen first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Nuveen's Finch Therapeutics Group, Inc. Common Stock position peaked at $176K in Q3 2021.
46 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.